A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID‑19 in Healthy Children

Trial status:Study Complete
Trial ID:
C4591007
NCT ID:
NCT04816643
EudraCT ID:
2020-005442-42
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Collaborator:
Pfizer
Study Complete

Trial Details

This is a Phase 1/2/3 study in healthy children.

Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age may subsequently be evaluated.

Medical Condition
  • COVID-19
    • Study Drug
  • Biological/Vaccine: BNT162b2 10mcg
    • See more
  • BNT162b2 20mcg
  • BNT162b2 30mcg
  • Biological/Vaccine: BNT162b2 3mcg
    • Phase
    Phase 2/Phase 3
    Type
    Interventional
    Estimated Enrolment
    11837
    Estimated Trial Date
    Mar 2021 - Oct 2023

    Trial Participant Requirements

    Age
    6 Months - 15 Years
    Sex
    Female & Male
    Healthy Volunteers
    Yes
    Inclusion and Exclusion Criteria
    Inclusion criteria

      Inclusion Criteria

    1. Male or female participants ≥6 months to \<12 years of age, at the time of randomization, at Visit 1 for the dose-finding/selected-dose evaluation. For the obtaining-serum-samples-for-potential-troponin I-testing portion of the study: Male or female participants between ≥5 and \<16 years of age.
    2. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
    3. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

        Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.

    4. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.
    5. Negative urine pregnancy test for female participants who are biologically capable of having children.
    6. Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.
    7. The participant or participant's parent(s)/legal guardian is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).

      8. Exclusion Criteria

    8. Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
    9. Phase 1 only: Known infection with HIV, HCV, or HBV.
    10. Receipt of medications intended to prevent COVID-19.
    11. Previous or current diagnosis of MIS-C.
    12. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results
    13. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
    14. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
    15. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
    16. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
    17. Female who is pregnant or breastfeeding.
    18. Previous vaccination with any coronavirus vaccine.
    19. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
    20. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.
    21. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
    22. Previous participation in other studies involving study intervention containing LNPs.
    23. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

    Trial Locations

    Location
    Status
    Location
    University of Alabama at Birmingham - School of Medicine
    Birmingham, Alabama, United States, 35233
    Status
    Location
    Phoenix Children's Hospital
    Phoenix, Arizona, United States, 85016
    Status
    Location
    Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California, United States, 90027
    Status
    Location
    SCPMG/Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California, United States, 90027
    Status
    Location
    Matrix Clinical Research
    Los Angeles, California, United States, 90057
    Status
    Location
    Madera Family Medical Group
    Madera, California, United States, 93637
    Status
    Go to page